These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 14742260)

  • 1. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.
    Redlich K; Görtz B; Hayer S; Zwerina J; Doerr N; Kostenuik P; Bergmeister H; Kollias G; Steiner G; Smolen JS; Schett G
    Am J Pathol; 2004 Feb; 164(2):543-55. PubMed ID: 14742260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
    Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
    Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
    Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
    Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis.
    Zwerina J; Tuerk B; Redlich K; Smolen JS; Schett G
    Arthritis Res Ther; 2006; 8(1):R22. PubMed ID: 16507121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin.
    Redlich K; Hayer S; Maier A; Dunstan CR; Tohidast-Akrad M; Lang S; Türk B; Pietschmann P; Woloszczuk W; Haralambous S; Kollias G; Steiner G; Smolen JS; Schett G
    Arthritis Rheum; 2002 Mar; 46(3):785-92. PubMed ID: 11920416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.
    Stolina M; Adamu S; Ominsky M; Dwyer D; Asuncion F; Geng Z; Middleton S; Brown H; Pretorius J; Schett G; Bolon B; Feige U; Zack D; Kostenuik PJ
    J Bone Miner Res; 2005 Oct; 20(10):1756-65. PubMed ID: 16160733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
    Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
    Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
    Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
    Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts.
    Gilbert LC; Chen H; Lu X; Nanes MS
    Bone; 2013 Sep; 56(1):174-83. PubMed ID: 23756233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
    Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of osteoprotegerin in arthritis.
    Schett G; Redlich K; Smolen JS
    Arthritis Res Ther; 2003; 5(5):239-45. PubMed ID: 12932284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.
    Morony S; Capparelli C; Lee R; Shimamoto G; Boone T; Lacey DL; Dunstan CR
    J Bone Miner Res; 1999 Sep; 14(9):1478-85. PubMed ID: 10469275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
    Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM
    Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.
    Onyia JE; Galvin RJ; Ma YL; Halladay DL; Miles RR; Yang X; Fuson T; Cain RL; Zeng QQ; Chandrasekhar S; Emkey R; Xu Y; Thirunavukkarasu K; Bryant HU; Martin TJ
    J Pharmacol Exp Ther; 2004 Apr; 309(1):369-79. PubMed ID: 14718597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.